COMP <GO>
BMY vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Bristol-Myers Squibb Company (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BMY 6
— JNJ 9
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: BMY
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
options-implied-move
6.80%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.10% | 67.90% | +3.20 | BMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.30% | 25.50% | -12.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 18.5x | -2.20 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 10.24% | 2.97% | +7.27 | BMY | /fcf-yield <GO> |
| Operating Margin | 17.90% | 34.70% | -16.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 14.60% | 28.50% | -13.90 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -0.20% | 6.00% | -6.20 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.02% | 0.00% | +4.02 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 5.59 | -3.35 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.80% | 7.20% | -0.40 | BMY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.7 | 60.4 | -5.64 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.08 | -0.10 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.6x | 23.0x | -6.40 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $125.40B | $662.49B | -$537.09B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMY REV | JNJ REV | BMY GROSS % | JNJ GROSS % | BMY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $48.19B | $94.19B | 71.1% | 67.9% | $12.85B | $19.70B |
| FY 2024 | $48.30B | $88.82B | 71.1% | 69.1% | $13.94B | $19.84B |
| FY 2023 | $45.01B | $85.16B | 44.0% | 44.0% | $11.83B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
JNJ // BETA 1.08